

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10519897
	Filing Date		2004-12-31
	First Named Inventor	Ingemar Starke	
	Art Unit	1624	
	Examiner Name	Mark L. Berch	
	Attorney Docket Number	133087.07001	

U.S.PATENTS							Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5306817		1994-04-26	Thiruvengadam et al.		
	2	5846966		1998-12-08	Rosenblum et al.		
	3	5767115		1998-06-16	Rosenblum et al.		
	4	5631365		1997-05-20	Rosenblum et al.		
	5	5739321		1998-04-14	Wu et al.		
	6	5886171		1999-03-23	Wu et al.		
If you wish to add additional U.S. Patent citation information please click the Add button.							Add
U.S.PATENT APPLICATION PUBLICATIONS							Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10519897
Filing Date		2004-12-31
First Named Inventor	Ingemar Starke	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	133087.07001	

	1					
--	---	--	--	--	--	--

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS

[Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	0250060	WO		2002-06-27	Avantis Pharma Deutschland GMB		<input type="checkbox"/>
	2	0250068	WO		2002-06-27	Aventis Pharma GMBH		<input type="checkbox"/>
	3	0250027	WO		2002-06-27	Aventis Pharma GMBH		<input type="checkbox"/>
	4	0218432	WO		2002-03-07	Aventis Pharma GMBH		<input type="checkbox"/>
	5	02066464	WO		2002-08-29	Noda Atsushi et al.		<input type="checkbox"/>
	6	524595	EP		1993-01-27	Schering Corporation		<input type="checkbox"/>
	7	9414433	WO		1994-07-07	Schering Corporation		<input type="checkbox"/>
	8	95/01961	WO		1995-01-19	Schering Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10519897
Filing Date		2004-12-31
First Named Inventor	Ingemar Starke	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	133087.07001	

9	9609827	WO		1996-04-04	Pfizer Inc.		<input type="checkbox"/>
10	9745406	WO		1997-12-04	Schering Corporation		<input type="checkbox"/>
11	0020623	WO		2000-04-13	Schering Corporation		<input type="checkbox"/>
12	0034240	WO		2000-06-15	Schering Corporation		<input type="checkbox"/>
13	0038725	WO		2000-07-06	G.D. Searle & Co.		<input type="checkbox"/>
14	0060107	WO		2000-10-12	Schering Corporation		<input type="checkbox"/>
15	0063703	WO		2000-10-26	Schering Corporation		<input type="checkbox"/>
16	02072104	WO		2002-09-19	Merck & Co., Inc.		<input type="checkbox"/>
17	02058685	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
18	02058696	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
19	02058731	WO		2008-08-01	Schering Corporation		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10519897
Filing Date		2004-12-31
First Named Inventor	Ingemar Starke	
Art Unit	1624	
Examiner Name	Mark L. Berch	
Attorney Docket Number	133087.07001	

20	02058732	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
21	02058733	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
22	02058734	WO		2002-08-01	Schering Corporation		<input type="checkbox"/>
23	02079174	WO		2002-10-10	Schering Corporation		<input type="checkbox"/>
24	02096415	WO		2002-12-05	Schering Corporation		<input type="checkbox"/>
25	03026644	WO		2003-04-03	Schering Corporation		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Clader et al., "2-Azetidinone Cholesterol Absorption Inhibitors: Structure-Activity Relationships on the Heterocyclic Nucleus," J. Med Chem (1996) 39:3684-3693.	<input type="checkbox"/>
	2	McKittrick et al., "Stereoselective synthesis and biological activity of cis azetidinones as cholesterol absorption inhibitors, Bioorganic & Medicinal Chemistry Letters (1996) 6(16):1947-1950.	<input type="checkbox"/>
	3	Burnett et al., "2-Azetidinones as Inhibitors of Cholesterol Absorption," J. Med Chem (1994) 12:1733-1736.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10519897
Filing Date	2004-12-31
First Named Inventor	Ingemar Starke
Art Unit	1624
Examiner Name	Mark L. Berch
Attorney Docket Number	133087.07001

4	Castaner et al., "Ezetimibe," Drugs of the Future (2000) 25(7):679-685.	<input type="checkbox"/>
5	Vaccaro et al., "Sugar-substituted 2-azetidinone cholesterol absorption inhibitors: Enhanced potency by modification of the sugar," Bioorganic & Medicinal Chemistry Letters (1998) 8:313-318.	<input type="checkbox"/>
6	Fu et al., "Process for preparing Ezetimibe intermediate by an acid enhanced chemo- and enantioselective CBS catalyzed ketone reduction," Tetrahedron Letters (2003) 44:801-804.	<input type="checkbox"/>
7	Kirkup et al., "(-)-SCH 57939: synthesis and pharmacological properties of a potent, metabolically stable cholesterol absorption inhibitor," Bioorganic & Medicinal Chemistry Letters (1996) 6(17):2069-2072.	<input type="checkbox"/>
8	Vaccaro et al., "Carboxy-substituted 2-azetidinones as cholesterol absorption inhibitors," Bioorganic & Medicinal Chemistry Letters (1998) 8:319-322.	<input type="checkbox"/>
9	Rosenblum et al., "Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 - hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.," J. Med Chem (1998) 41:973-980.	<input type="checkbox"/>
10	Wu et al., "A Novel One-Step Diastereo- and Enantioselective Formation of trans-Azetidinones and Its Application to the Total Synthesis of Cholesterol Absorption Inhibitors," J. Org. Chem (1999) 64:3714-3718.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.